Year-End Report 2008

Year-End Report 2008

January - December
• Group revenues from sales of goods and royalties amounted to 1,272 (1,318)
MSEK. 
• Earnings per share amounted to 0.34 (3.17*) SEK. 
• Operating income amounted to 50 (371*) MSEK. 
• Revenues within the Esthetics product area amounted to 1,037 (1,073) MSEK and
operating income was 172 (533*) MSEK.
• Income after tax amounted to 33 (315*) MSEK.

October - December
• Group revenues from sales of goods and royalties amounted to 336 (336) MSEK
during the fourth quarter and operating income amounted to -50 (-10) MSEK. 
• Income after tax amounted to -44 (-14) MSEK during the fourth quarter. The
results for the fourth quarter include a restructuring cost of 31 MSEK and
external costs of 35 MSEK in connection with Ivytan AB's bid for Q-Med.

Important events after the end of the year
• Q-Med has obtained registration approval for Restylane® in China.
• Q-Med and Palomar Medical Technologies, Inc., have terminated the
international distribution agreement that was entered into in January 2008.
• At Q-Med's Extraordinary General Meeting on February 4 a resolution was
adopted to re-elect Bertil Hult, Anders Milton and Bengt Ågerup as Board members
of        Q-Med. Ulf Mattsson, Tomas Nicolin and Kristina Persson were newly
elected. The meeting also elected Anders Milton as Chairman of the Board.
• The Board proposes that no dividend be paid for 2008.

*  Operating income for 2007 includes the supplementary purchase sum of 200 MSEK
that Q-Med received from Medicis when Restylane Perlane™ was approved for sales
in the USA.

Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: + 46 (0)70 -974 9025  
Alexander Kotsinas, Vice President and CFO
Tel: +46 (0)73-500 1111
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70-974 9015

Q-Med AB is a biotechnology/medical device company. The company develops,
manufactures, markets, and sells primarily medical implants. The majority of the
products are based on the company's patented technology, NASHA™, for the
production of stabilized non-animal hyaluronic acid. The product portfolio today
contains: Restylane® for filling lines and folds, contouring and creating volume
in the face, Macrolane™ for body contouring, Durolane™ for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta™ for the treatment of fecal incontinence. Sales are made through the
company's own subsidiaries or distributors in over 70 countries. Q Med today has
just over 650 coworkers, with close to 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap
segment of the NASDAQ OMX Nordic.